New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE…
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the…
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients…
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy…
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology…
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class…
IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma…
BSB-1001 is the first product candidate from the TCX-101 platformData supports BSB-1001 as a potential treatment to improve outcomes for…
- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - -…
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint…